Wordt geladen...
Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity
BACKGROUND: Bortezomib (Bz) is a proteasome inhibitor that directly targets antibody-producing plasma cells. We recently reported the first randomized control trial that evaluated the effects of Bz in patients with systemic lupus erythematosus (SLE). In that study, we demonstrated that Bz treatment...
Bewaard in:
| Gepubliceerd in: | Arthritis Res Ther |
|---|---|
| Hoofdauteurs: | , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5553803/ https://ncbi.nlm.nih.gov/pubmed/28800777 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-017-1397-7 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|